Jeez these guys arent messing around any more. 6 more potential eye targets. I also liked the bit tagged on at the end still targetting DMD. Imagine if they also come up with something in the oncology field. . No longer seems to be coasting along, now seems determinedly trying to get something into clinic.
"As the Company progresses its retinal drug pipeline, it continues to explore other areas where it can leverage its growing capability in ‘precision medicines’ (drugs that act inside affected cells). An animal model of Duchenne Muscular Dystrophy has recently been used to evaluate PYC’s ability to deliver an ASO (antisense oligonucleotide) to a muscle cell using one of its CPPs (cell penetrating peptides). The processing of tissue samples is still pending and the results are expected within the first half of 2020."
PYC Price at posting:
5.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)